PHASE 1B ADVENT-AML TRIAL OF CHM CORE-NK ADVANCES TO NEXT...

PHASE 1B ADVENT-AML TRIAL OF CHM CORE-NK ADVANCES TO NEXT
COHORT
 ADVENT-AML is the first trial to evaluate the synergy of NK cell therapy in combination
with the current standard of care for acute myeloid leukemia (AML)
 Three patients were treated in first cohort; none experienced dose-limiting toxicities
 Second cohort now open to enrolment, testing higher dose of CHM CORE-NK
Sydney, Australia, 5 June 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the
“Company”), an Australian leader in cell therapy, is pleased to announce that the Phase 1B
ADVENT-AML trial of CHM CORE-NK has advanced to the next planned cohort.
The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated trial
currently open to enrollment at The University of Texas MD Anderson Cancer Center under
Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia.
This is the first trial to evaluate the synergy of NK cell therapy in combination with the current
standard of care for AML, Azacitidine and Venetoclax (aza/ven).
In the first cohort, which opened to enrolment in Q1 2024, three subjects with relapsed or
refractory AML received CHM CORE-NK at Dose Level 1, in combination with standard-of-care
aza/ven. No dose-limiting toxicities (DLTs) were reported during the 28-day DLT evaluation
period.
Following review of the data from the first three patients, the safety monitoring committee has
authorized the trial to advance to the next cohort, in which three subjects with relapsed or
refractory AML will receive CHM CORE-NK at Dose Level 2 in combination with aza/ven. The
study is designed to then enrol up to 20 subjects with newly diagnosed AML who are not
eligible for intensive chemotherapy or allogeneic stem cell transplant.
“It has been great to see the progress of this clinical trial for these AML patients” said Dr
Rebecca McQualter, Chief Operating Officer of Chimeric